Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Anika Therapeutics, Inc. (NasdaqNM:ANIK)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | SEC | Msgs | Financials
Recent Events
Aug 14Earnings Announcement
Location
236 West Cummings Park
Woburn, MA 01801
Phone: (781) 932-6616
Fax: (781) 935-4120
Email: smoran@anikatherapeutics.com
Employees (last reported count): 64
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 38%
·Institutional: 4% (7% of float)
(17 institutions)
·Net Inst. Buying: 216.0K shares (+32.68%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products and devices intended to promote the repair, protection and healing of bone, cartilage and soft tissue. Orthovisc is a hyaluronic acid (HA) product used in the treatment of some forms of osteoarthritis in humans, and is currently approved for sale and marketed in Canada, Europe, Turkey and Israel. Hyvisc is a HA product used in the treatment of equine osteoarthritis. Amvisc and Amvisc Plus are HA products used as viscoelastic supplements in ophthalmic surgery for Bausch & Lomb Surgical. The Company is currently developing Incert, which is a family of HA-based products designed for use in the prevention of post-surgical adhesions. In collaboration with Orquest, Inc., Anika also has exclusive rights to produce Ossigel, an injectable formulation of basic fibroblast growth factor combined with HA and designed to accelerate the healing of bone fractures.
More from Market Guide: Expanded Business Description

Financial Summary
Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products based on hyaluronic acid (HA) used to promote the protection and healing of bone, cartilage and soft tissue. For the six months ended 6/30/01, revenues fell 21% to $5.1 million. Net loss totaled $5 million, up from $783 thousand. Revenues reflect lower unit prices. Higher loss also reflects the underutilization of manufacturing capacity and a $951 thousand litigation settlement charge.
More from Market Guide: Significant Developments

Officers
FY2000 Pay

Douglas Potter, 50
CEO, Chief Financial Officer
$196K
Charles Sherwood, Ph.D., 54
Pres, COO
208K
Michael Slater, 54
VP of Operations
199K
Edward Ross, Jr., 44
VP of Sales and Marketing
184K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:ANIKAs of 31-Aug-2001
Price and Volume
52-Week Low
on 29-Dec-2000
$0.688
Recent Price$1.05 
52-Week High
on 7-Sep-2000
$1.844
Beta1.50 
Daily Volume (3-month avg)13.5K
Daily Volume (10-day avg)7,000 
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-40.0%
52-Week Change
relative to S&P500
-19.5%
Share-Related Items
Market Capitalization$10.4M
Shares Outstanding9.93M
Float6.20M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$2.20 
Earnings (ttm)-$0.40 
Earnings (mrq)-$0.27 
Sales (ttm)$1.50 
Cash (mrq)$1.58 
Valuation Ratios
Price/Book (mrq)0.48 
Price/EarningsN/A 
Price/Sales (ttm)0.70 
Income Statements
Sales (ttm)$14.9M
EBITDA (ttm)-$3.90M
Income available to common (ttm)-$4.01M
Profitability
Profit Margin (ttm)-26.9%
Operating Margin (ttm)-33.8%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-13.84%
Return on Equity (ttm)-16.32%
Financial Strength
Current Ratio (mrq)5.83 
Debt/Equity (mrq)0 
Total Cash (mrq)$15.7M
Short Interest
As of 8-Aug-2001
Shares Short0 
Shares Short
(Prior Month)
0 
Daily Volume20.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.